Lantern Pharma Secures EU Patent for AI-Designed Cancer Drug LP-284
Lantern Pharma (NASDAQ: LTRN) has achieved a significant milestone with the European Patent Office issuing a notice of allowance for a composition of matter patent for LP-284, its clinical-stage drug...